PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,771,133 | -20.4% | 1,785,239 | +3.9% | 0.00% | -25.0% |
| Q2 2023 | $68,846,110 | +0.3% | 1,718,146 | +2.1% | 0.00% | 0.0% |
| Q1 2023 | $68,656,010 | -45.0% | 1,682,333 | -47.9% | 0.00% | 0.0% |
| Q4 2022 | $124,754,006 | +38.0% | 3,231,132 | +90.1% | 0.00% | -33.3% |
| Q3 2022 | $90,403,000 | -6.3% | 1,699,628 | +2.7% | 0.01% | 0.0% |
| Q2 2022 | $96,456,000 | -21.3% | 1,654,473 | +3.0% | 0.01% | 0.0% |
| Q1 2022 | $122,551,000 | +33.1% | 1,605,758 | +5.0% | 0.01% | +50.0% |
| Q4 2021 | $92,060,000 | +12.4% | 1,530,001 | +4.6% | 0.00% | 0.0% |
| Q3 2021 | $81,882,000 | -8.6% | 1,462,177 | -1.0% | 0.00% | -20.0% |
| Q2 2021 | $89,622,000 | -10.7% | 1,476,967 | +3.2% | 0.01% | -16.7% |
| Q1 2021 | $100,358,000 | +17.8% | 1,431,840 | +0.6% | 0.01% | +20.0% |
| Q4 2020 | $85,191,000 | +0.3% | 1,423,654 | +0.8% | 0.01% | -16.7% |
| Q3 2020 | $84,944,000 | +8.6% | 1,412,910 | -5.2% | 0.01% | 0.0% |
| Q2 2020 | $78,190,000 | +66.1% | 1,490,184 | +6.2% | 0.01% | +50.0% |
| Q1 2020 | $47,065,000 | -21.9% | 1,403,659 | +5.6% | 0.00% | 0.0% |
| Q4 2019 | $60,233,000 | +19.2% | 1,329,650 | +0.2% | 0.00% | 0.0% |
| Q3 2019 | $50,519,000 | +23.3% | 1,327,004 | +40.8% | 0.00% | +33.3% |
| Q2 2019 | $40,977,000 | +12.4% | 942,210 | -1.7% | 0.00% | 0.0% |
| Q1 2019 | $36,468,000 | -9.0% | 958,180 | +2.9% | 0.00% | -25.0% |
| Q4 2018 | $40,059,000 | -17.5% | 931,175 | -5.7% | 0.00% | 0.0% |
| Q3 2018 | $48,529,000 | +48.5% | 987,396 | -3.1% | 0.00% | +33.3% |
| Q2 2018 | $32,671,000 | -9.2% | 1,019,445 | -11.7% | 0.00% | 0.0% |
| Q1 2018 | $35,984,000 | -20.1% | 1,155,112 | +17.1% | 0.00% | -25.0% |
| Q4 2017 | $45,038,000 | +14.8% | 986,585 | -5.6% | 0.00% | +33.3% |
| Q3 2017 | $39,237,000 | -26.4% | 1,044,795 | -6.6% | 0.00% | -40.0% |
| Q2 2017 | $53,340,000 | +5.6% | 1,118,083 | +1.0% | 0.01% | 0.0% |
| Q1 2017 | $50,499,000 | +45.0% | 1,107,356 | +2.7% | 0.01% | +66.7% |
| Q4 2016 | $34,834,000 | -7.3% | 1,078,693 | -1.8% | 0.00% | -25.0% |
| Q3 2016 | $37,584,000 | -7.0% | 1,098,184 | -8.3% | 0.00% | 0.0% |
| Q2 2016 | $40,406,000 | -31.3% | 1,197,912 | +8.0% | 0.00% | -33.3% |
| Q1 2016 | $58,792,000 | -27.9% | 1,109,611 | +4.4% | 0.01% | -33.3% |
| Q4 2015 | $81,591,000 | +82.4% | 1,062,515 | -2.4% | 0.01% | +80.0% |
| Q3 2015 | $44,743,000 | -42.5% | 1,088,596 | -1.0% | 0.01% | -37.5% |
| Q2 2015 | $77,789,000 | -19.9% | 1,100,006 | +0.7% | 0.01% | -20.0% |
| Q1 2015 | $97,068,000 | +4.8% | 1,092,454 | +4.6% | 0.01% | +11.1% |
| Q4 2014 | $92,625,000 | -5.1% | 1,044,681 | +3.8% | 0.01% | -10.0% |
| Q3 2014 | $97,563,000 | +12.2% | 1,006,665 | +6.4% | 0.01% | +11.1% |
| Q2 2014 | $86,935,000 | +34.1% | 946,388 | +2.2% | 0.01% | +28.6% |
| Q1 2014 | $64,836,000 | +5.9% | 926,334 | -27.8% | 0.01% | +75.0% |
| Q4 2013 | $61,229,000 | +64.0% | 1,282,761 | +65.3% | 0.00% | -20.0% |
| Q3 2013 | $37,329,000 | +48.0% | 776,204 | -10.8% | 0.01% | +66.7% |
| Q2 2013 | $25,227,000 | – | 869,841 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |